The Indian pharmaceutical market size is expected to grow to USD 100 billion by 2025. By 2020, India is likely to be among the top-3 pharmaceutical markets by incremental growth and the sixth largest market globally in absolute size. The Indian packaging industry constitutes about 4 percent of the global packaging industry making it a crucial factor in India's pharma growth story.
Everything you need to know to get up to speed with the world of pharma.
Indian drug cos are falling woefully short of their global peers in arming medical representatives with desired digital tools, according to a new survey of field representatives by Indegene,
The USFDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market. Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda (mesalamine), the company said in a BSE filing.
IDA (Industrial Development Agency) Ireland CEO Martin D Shanahan said that Indian companies based in the UK are welcome to shift operations in Ireland as it will continue to remain part of the European Union even after Brexit.
In an interview to CNBC-TV18, Jaspal Bindra, Executive Chairman of Centrum Group spoke about the theme of the conference and what the underlying conversations are considering the record highs that the market is sitting at.
The pharmaceutical sector has been missing for the recent rally on Dalal Street and the Nifty Pharma Index is down 10 percent in May while the Nifty gained over 3 percent.
The one-day strike is likely to reduce the supply of drugs to the market, thereby affecting patients. However, medicine shops inside hospitals and day-and-night outlets will remain open.
"There are major structural changes taking place in the pharma business across the globe whether it is US or India or Japan and that will put pressure," said Kamal K. Sharma, vice chairman of Lupin in an exclusive interview to Moneycontrol.
The S&P BSE Sensex pared gains in the last two trading sessions and eventually closed in the green largely led by weak global cues.
The pharma major reported 49.2 percent YoY decline in the net profit to Rs 380.2 crore in the fourth quarter ended March on account of drop in US sales and a one-time provisioning
In an interview to CNBC-TV18, Amey Chalke, Research Analyst at HDFC Securities spoke about the likely reasons for weakness witnessed in the pharma space.
Total revenues of the company rose 3.4 percent to Rs 466.6 crore during the quarter while EBITDA grew 5 percent to Rs 127.4 crore.
Monitoring allows government to make sure that no manufacturer or importer or distributor is allowed to increase MRP of a non-scheduled drug more than 10% of MRP during preceding twelve months
"This approval is the outcome of the inspection conducted in December 2016. The plant contributes to 40 per cent of our international business," a company statement said here.
He feels, valuations are stretched in mid-. small- and micro-cap segment adding that he large cap valuations are still looking attractive
The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name 'Velpanat', Natco Pharma said in a BSE filing.
Continuing last week's trend, generics, stents, drug price control and the National Pharmaceutical Pricing Authority (NPPA) kept hogging headlines.
With the latest additions, the government has brought 732 essential drugs under price control in the National List of Essential Medicines (NLEM) since April 2016.
Pharma stocks are in focus as the health ministry has asked doctors to prescribe generic names of drugs versus branded names.
The Indian Pharmaceutical Alliance (IPA) said that due to the nature of the current off-patent medicines market in India, if such a step were to be followed, the choice of products will be shifted from doctors to chemists, not patients.
Modi said his government brought in a health policy after 15 years and capped the prices of medicines and stents, which has angered some pharmaceutical companies.
Analysts predict the March quarter will be tough with revenue growth moderating to 5-6 percent owing to the absence of any significant launches and pricing pressure in US, which accounts for half their sales
During the inspection, the FDA investigator observed specific violations such as the quality system not fully ensuring data integrity, the regulator said.
The whole world might be worried about IT and pharma amid regulatory hurdles as well as rising rupee but fundamentally they remain a strong play, Sheth told CNBC-TV18.